|$ amounts in millions, except per share amounts|
|GAAP Diluted EPS||0.42||(0.43||)||**|
|Non-GAAP Diluted EPS||0.46||0.41||12%|
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.